Developer docs
API playgroundTry for free, no card

Search company profiles

X4 Pharmaceuticals

Full company profile

uuid0000tb1

Namestring
X4 Pharmaceuticals
Legal namestring
X4 Pharmaceuticals, Inc.
Websiteurl
x4pharma.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

X4 Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company founded in 2014 that develops oral small-molecule therapeutics targeting the CXCR4/CXCL12 pathway for rare diseases of the immune system. Its lead asset, mavorixafor (marketed as XOLREMDI), is an oral, once-daily CXCR4 receptor antagonist that regulates mobilization of white blood cells from bone marrow into circulation; it is the first drug ever approved in the United States (April 2024) and the European Union (April 2026) for the treatment of WHIM syndrome in patients 12 years and older. The company is advancing mavorixafor through the pivotal global Phase 3 4WARD trial in chronic neutropenia, a larger label opportunity, with enrollment of 176 patients targeted for completion by Q3 2026 and potential 2028 approval.

The business operates a hybrid commercial model: in the United States, X4 deploys its own field force of Medical Science Liaisons, Patient Diagnostic Liaisons, and a nurse educator and supports patients through the X4Connect program, while international commercialization is executed via specialist partners (Norgine for Europe, Australia, and New Zealand; taiba rare for the MENA region). Revenue is generated from XOLREMDI net product sales in the US, licensing and milestone payments from partners, and royalties; FY2025 total revenue was approximately $35.1 million ($6.5 million product plus $28.6 million license), with $233.7 million of cash at the end of Q1 2026 providing runway through 2028. The company is publicly traded on Nasdaq under XFOR and has executed a substantial leadership refresh in 2025 oriented toward pipeline execution and value-creating transactions.

Short descriptiontext

X4 Pharmaceuticals is a Boston-based biopharmaceutical company that develops and commercializes oral CXCR4 antagonists for rare immune disorders, with its approved product XOLREMDI (mavorixafor) serving WHIM syndrome patients in the US and EU and an ongoing Phase 3 program in chronic neutropenia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, CXCR4 antagonists, WHIM syndrome treatment, oral small molecules, primary immunodeficiency drugs
Industry3 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1XOLREMDI Product Sales
TypeOne Time License
Description

Net product sales of XOLREMDI (mavorixafor) in the United States following FDA approval in April 2024. The company deployed a commercial team including field force of Medical Science Liaisons, Patient Diagnostic Liaisons, and nurse educator to drive sales.

biospace.com
2Licensing and Milestone Revenue
TypeLicensing Royalties
Description

License agreement with Norgine worth up to €226 million in milestones plus escalating double-digit royalties for European commercialization of XOLREMDI. Includes one-time license revenue recognized from prior agreements.

stocktitan.net
3Full Year 2025 Revenue
TypeOne Time License
Description

Full year 2025 revenue of $6.5 million in net product sales and $28.6 million in license revenue, totaling approximately $35.1 million.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1XOLREMDI
Description

FDA-approved oral, once-daily therapy for patients 12 years and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes

x4pharma.com
+1 more record
Core offering1 text field

X4 Pharmaceuticals develops and commercializes XOLREMDI® (mavorixafor), an oral, once-daily CXCR4 receptor antagonist approved in the US (April 2024) and EU (April 2026) as the first treatment for WHIM syndrome in patients aged 12 and older. The company also advances mavorixafor through a global pivotal Phase 3 4WARD clinical trial for chronic neutropenia, with a 176-patient enrollment target and potential 2028 commercial approval. X4 supports patients and providers through its X4Connect program offering insurance support and copay assistance for eligible US patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Approximately 40% reduction in total infection score vs placebo in Phase 3 WHIM trial
+4 more records
Product overview1 text field

X4 Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system. The company's primary product is XOLREMDI® (mavorixafor), an FDA-approved oral therapy for WHIM syndrome launched in the U.S. in May 2024 and approved in the EU in April 2026, with commercialization led by partner Norgine in Europe. The company is advancing mavorixafor through the pivotal global Phase 3 4WARD trial for chronic neutropenic disorders, with patient enrollment targeted for completion by Q3 2026. X4 supports patients through its X4Connect program providing treatment support, insurance assistance, and copay programs, and maintains an Expanded Access Program for eligible WHIM syndrome patients outside the U.S.

Product and service2 records
1XOLREMDI® (mavorixafor)
CategoryApproved Rare Disease Pharmaceutical Product
Description

FDA- and EU-approved oral, once-daily CXCR4 receptor antagonist therapy for patients 12 years and older with WHIM syndrome, designed to increase the number of circulating mature neutrophils and lymphocytes. Sold in the US through X4's direct commercial field force and supported ex-US through licensing partners Norgine (EU, Australia, New Zealand) and taiba rare (MENA).

2Mavorixafor (investigational chronic neutropenia program)
CategoryInvestigational Rare Disease Pharmaceutical Product
Description

Investigational development of mavorixafor as an oral, once-daily therapy for chronic neutropenic disorders, targeting the same CXCR4/CXCL12 pathway to mobilize white blood cells. Designed as an oral alternative or complement to injectable G-CSF, the only approved therapy for severe chronic neutropenia for the past 30 years. Target US market of approximately 15,000 symptomatic chronic neutropenia patients representing a $400-600 million peak revenue opportunity.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-01
Description

Licensing and supply agreement with Norgine, a leading European specialist pharmaceutical company, for commercialization of mavorixafor (XOLREMDI) in the European Union, Australia, and New Zealand. Under the agreement, Norgine leads commercialization and assumes responsibility for all market access activities, while X4 manufactures and supplies the drug. The agreement is worth up to €226 million in milestones plus escalating double-digit royalties. The European Commission granted marketing authorization in April 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive agreement with taiba rare for distribution and commercialization of XOLREMDI in Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt, following any regulatory approvals in the territories. taiba rare has specialty and orphan drug marketing, sales, and distribution expertise in the MENA region.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage rare disease biotech focused on oral therapies for ultra-rare genetic disorders (Fabry, Pompe). Directly comparable business model to X4: small-molecule, specialty commercial team, similar patient population scale. CCO Mark Baldry previously led global commercial at Amicus.

TypeDirect peer
Description

Mid-cap rare disease biopharma with multiple approved specialty therapies and ongoing pipeline in inherited conditions. Comparable structure: orphan-drug commercial model, regulatory exclusivity leverage, partnership-based international expansion.

TypeDirect peer
Description

Clinical-to-commercial rare disease biotech developing and commercializing therapies for ultra-rare genetic diseases. Similar size, patient population profile, and reliance on orphan drug exclusivity economics.

TypeDirect peer
Description

Ultra-rare disease biotech with FDA-approved setmelanotide (Imcivree) for rare genetic obesity disorders. Comparable profile: small addressable population, oral/specialty therapy, MSL-driven commercial model. Board member Murray Stewart previously served as CMO of Rhythm.

TypeDirect peer
Description

European specialty biopharma focused on rare diseases, recently completed $1.7B acquisition of CTI BioPharma (X4 Executive Chair Adam Craig's prior company). Directly comparable as Norgine's competitor in European orphan drug distribution and rare-disease commercialization.

TypeBroad incumbent
Description

Established rare disease franchise within AstraZeneca, focused on complement-mediated and metabolic rare disorders. Comparable commercial model in ultra-rare disease; broader portfolio and larger scale than X4.

TypeBroad incumbent
Description

Larger rare-disease specialist with multiple approved therapies for serious specialty conditions. Comparable in commercial sophistication and orphan-drug focus, though operates at materially greater scale.

TypeBroad incumbent
Description

Sanofi's rare disease franchise pioneered the orphan drug commercial model. Highly relevant precedent: founder Paula Ragan led strategic partnering at Genzyme Rare Disease, and Gary Bridger held senior R&D roles there. Sanofi's Genzyme unit established the playbook X4 is executing.

TypeDirect peer
Description

Small-cap hematology/rare disease biotech acquired by Sobi for $1.7B in 2023. Multiple members of X4's current leadership (Craig, Volpone, Kirske) previously held senior roles at CTI, providing a directly comparable operating blueprint for orphan drug commercialization and exit.

TypeRegional player
Description

European-headquartered specialty pharma with significant rare disease focus. Comparable to Norgine as a potential distribution partner for X4 in non-US geographies; operates an established rare disease commercial infrastructure in Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

X4 Pharmaceuticals

Rare Disease Biopharmaceuticalsx4pharma.com

X4 Pharmaceuticals is a Boston-based biopharmaceutical company that develops and commercializes oral CXCR4 antagonists for rare immune disorders, with its approved product XOLREMDI (mavorixafor) serving WHIM syndrome patients in the US and EU and an ongoing Phase 3 program in chronic neutropenia.

What X4 Pharmaceuticals does

X4 Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company founded in 2014 that develops oral small-molecule therapeutics targeting the CXCR4/CXCL12 pathway for rare diseases of the immune system. Its lead asset, mavorixafor (marketed as XOLREMDI), is an oral, once-daily CXCR4 receptor antagonist that regulates mobilization of white blood cells from bone marrow into circulation; it is the first drug ever approved in the United States (April 2024) and the European Union (April 2026) for the treatment of WHIM syndrome in patients 12 years and older. The company is advancing mavorixafor through the pivotal global Phase 3 4WARD trial in chronic neutropenia, a larger label opportunity, with enrollment of 176 patients targeted for completion by Q3 2026 and potential 2028 approval.

The business operates a hybrid commercial model: in the United States, X4 deploys its own field force of Medical Science Liaisons, Patient Diagnostic Liaisons, and a nurse educator and supports patients through the X4Connect program, while international commercialization is executed via specialist partners (Norgine for Europe, Australia, and New Zealand; taiba rare for the MENA region). Revenue is generated from XOLREMDI net product sales in the US, licensing and milestone payments from partners, and royalties; FY2025 total revenue was approximately $35.1 million ($6.5 million product plus $28.6 million license), with $233.7 million of cash at the end of Q1 2026 providing runway through 2028. The company is publicly traded on Nasdaq under XFOR and has executed a substantial leadership refresh in 2025 oriented toward pipeline execution and value-creating transactions.

X4 Pharmaceuticals firmographics

Firmographics
Name
X4 Pharmaceuticals
Legal name
X4 Pharmaceuticals, Inc.
Website
https://x4pharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
X4 Pharmaceuticals is a Boston-based biopharmaceutical company that develops and commercializes oral CXCR4 antagonists for rare immune disorders, with its approved product XOLREMDI (mavorixafor) serving WHIM syndrome patients in the US and EU and an ongoing Phase 3 program in chronic neutropenia.
Ownership category
akta.pro rank

X4 Pharmaceuticals industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Rare disease therapeutics
  • CXCR4 antagonists
  • WHIM syndrome treatment
  • Oral small molecules
  • Primary immunodeficiency drugs

Where X4 Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

X4 Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. XOLREMDI Product Sales: Net product sales of XOLREMDI (mavorixafor) in the United States following FDA approval in April 2024. The company deployed a commercial team including field force of Medical Science Liaisons, Patient Diagnostic Liaisons, and nurse educator to drive sales.
  2. Licensing and Milestone Revenue: License agreement with Norgine worth up to €226 million in milestones plus escalating double-digit royalties for European commercialization of XOLREMDI. Includes one-time license revenue recognized from prior agreements.
  3. Full Year 2025 Revenue: Full year 2025 revenue of $6.5 million in net product sales and $28.6 million in license revenue, totaling approximately $35.1 million.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

X4 Pharmaceuticals product offering

Product offering

Core offering

X4 Pharmaceuticals develops and commercializes XOLREMDI® (mavorixafor), an oral, once-daily CXCR4 receptor antagonist approved in the US (April 2024) and EU (April 2026) as the first treatment for WHIM syndrome in patients aged 12 and older. The company also advances mavorixafor through a global pivotal Phase 3 4WARD clinical trial for chronic neutropenia, with a 176-patient enrollment target and potential 2028 commercial approval. X4 supports patients and providers through its X4Connect program offering insurance support and copay assistance for eligible US patients.

Product overview

X4 Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system. The company's primary product is XOLREMDI® (mavorixafor), an FDA-approved oral therapy for WHIM syndrome launched in the U.S. in May 2024 and approved in the EU in April 2026, with commercialization led by partner Norgine in Europe. The company is advancing mavorixafor through the pivotal global Phase 3 4WARD trial for chronic neutropenic disorders, with patient enrollment targeted for completion by Q3 2026. X4 supports patients through its X4Connect program providing treatment support, insurance assistance, and copay programs, and maintains an Expanded Access Program for eligible WHIM syndrome patients outside the U.S.

Differentiator

Problem solved

Functional benefit

Brands

  • XOLREMDI: FDA-approved oral, once-daily therapy for patients 12 years and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes
  • X4Connect

Products and services

  • XOLREMDI® (mavorixafor) FDA- and EU-approved oral, once-daily CXCR4 receptor antagonist therapy for patients 12 years and older with WHIM syndrome, designed to increase the number of circulating mature neutrophils and lymphocytes. Sold in the US through X4's direct commercial field force and supported ex-US through licensing partners Norgine (EU, Australia, New Zealand) and taiba rare (MENA).
  • Mavorixafor (investigational chronic neutropenia program) Investigational development of mavorixafor as an oral, once-daily therapy for chronic neutropenic disorders, targeting the same CXCR4/CXCL12 pathway to mobilize white blood cells. Designed as an oral alternative or complement to injectable G-CSF, the only approved therapy for severe chronic neutropenia for the past 30 years. Target US market of approximately 15,000 symptomatic chronic neutropenia patients representing a $400-600 million peak revenue opportunity.

Quantifiable outcome

  • Approximately 40% reduction in total infection score vs placebo in Phase 3 WHIM trial
  • +4 more outcomes

Companies that use X4 Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

X4 Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

X4 Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • NorginecoreChannel Partner/ Reseller/ Distributor · 1 January 2025Licensing and supply agreement with Norgine, a leading European specialist pharmaceutical company, for commercialization of mavorixafor (XOLREMDI) in the European Union, Australia, and New Zealand. Under the agreement, Norgine leads commercialization and assumes responsibility for all market access activities, while X4 manufactures and supplies the drug. The agreement is worth up to €226 million in milestones plus escalating double-digit royalties. The European Commission granted marketing authorization in April 2026.
  • taiba rarecoreChannel Partner/ Reseller/ DistributorExclusive agreement with taiba rare for distribution and commercialization of XOLREMDI in Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt, following any regulatory approvals in the territories. taiba rare has specialty and orphan drug marketing, sales, and distribution expertise in the MENA region.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

X4 Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Amicus Therapeutics: Commercial-stage rare disease biotech focused on oral therapies for ultra-rare genetic disorders (Fabry, Pompe). Directly comparable business model to X4: small-molecule, specialty commercial team, similar patient population scale. CCO Mark Baldry previously led global commercial at Amicus.
  • BioMarin Pharmaceutical: Mid-cap rare disease biopharma with multiple approved specialty therapies and ongoing pipeline in inherited conditions. Comparable structure: orphan-drug commercial model, regulatory exclusivity leverage, partnership-based international expansion.
  • Ultragenyx Pharmaceutical: Clinical-to-commercial rare disease biotech developing and commercializing therapies for ultra-rare genetic diseases. Similar size, patient population profile, and reliance on orphan drug exclusivity economics.
  • Rhythm Pharmaceuticals: Ultra-rare disease biotech with FDA-approved setmelanotide (Imcivree) for rare genetic obesity disorders. Comparable profile: small addressable population, oral/specialty therapy, MSL-driven commercial model. Board member Murray Stewart previously served as CMO of Rhythm.
  • Swedish Orphan Biovitrum (Sobi): European specialty biopharma focused on rare diseases, recently completed $1.7B acquisition of CTI BioPharma (X4 Executive Chair Adam Craig's prior company). Directly comparable as Norgine's competitor in European orphan drug distribution and rare-disease commercialization.
  • CTI BioPharma: Small-cap hematology/rare disease biotech acquired by Sobi for $1.7B in 2023. Multiple members of X4's current leadership (Craig, Volpone, Kirske) previously held senior roles at CTI, providing a directly comparable operating blueprint for orphan drug commercialization and exit.

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Established rare disease franchise within AstraZeneca, focused on complement-mediated and metabolic rare disorders. Comparable commercial model in ultra-rare disease; broader portfolio and larger scale than X4.
  • Vertex Pharmaceuticals: Larger rare-disease specialist with multiple approved therapies for serious specialty conditions. Comparable in commercial sophistication and orphan-drug focus, though operates at materially greater scale.
  • Genzyme (Sanofi): Sanofi's rare disease franchise pioneered the orphan drug commercial model. Highly relevant precedent: founder Paula Ragan led strategic partnering at Genzyme Rare Disease, and Gary Bridger held senior R&D roles there. Sanofi's Genzyme unit established the playbook X4 is executing.

Regional players

  • Recordati Rare Diseases: European-headquartered specialty pharma with significant rare disease focus. Comparable to Norgine as a potential distribution partner for X4 in non-US geographies; operates an established rare disease commercial infrastructure in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

X4 Pharmaceuticals social profiles

Digital presence

X4 Pharmaceuticals compliance and trust

Trust signal

Compliance2 records

X4 Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

X4 Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles14 records

X4 Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

X4 Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X4 Pharmaceuticals

What does X4 Pharmaceuticals do?

X4 Pharmaceuticals develops and commercializes XOLREMDI® (mavorixafor), an oral, once-daily CXCR4 receptor antagonist approved in the US (April 2024) and EU (April 2026) as the first treatment for WHIM syndrome in patients aged 12 and older. The company also advances mavorixafor through a global pivotal Phase 3 4WARD clinical trial for chronic neutropenia, with a 176-patient enrollment target and potential 2028 commercial approval. X4 supports patients and providers through its X4Connect program offering insurance support and copay assistance for eligible US patients.

Is X4 Pharmaceuticals a public or private company?

X4 Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was X4 Pharmaceuticals founded?

X4 Pharmaceuticals was founded in 2014. It employs 51 to 100 people.

Where is X4 Pharmaceuticals based?

X4 Pharmaceuticals is headquartered in Boston, United States, in the North America region.

How does X4 Pharmaceuticals make money?

Three revenue lines are on record. XOLREMDI Product Sales are the primary driver. The others are licensing and Milestone Revenue and full Year 2025 Revenue.

Who are X4 Pharmaceuticals's main competitors?

Direct peers on record are Amicus Therapeutics, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, Swedish Orphan Biovitrum (Sobi) and CTI BioPharma. Broad incumbents are Alexion (AstraZeneca Rare Disease), Vertex Pharmaceuticals and Genzyme (Sanofi). Recordati Rare Diseases is listed as a regional player.

Does X4 Pharmaceuticals have an API?

No public API is recorded for X4 Pharmaceuticals.

What industry is X4 Pharmaceuticals in?

X4 Pharmaceuticals's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.60X4 Pharmaceuticals reported Q4 revenue of $2.9M, beating estimates by 25%, but posted a statutory loss of $0.16 per share. Analysts' consensus price target fell 57% to $11.60, with revenue forecast to decline 32% to $11.6M in 2027. The company is expected to lag the industry's 21% annual growth.The future of tradingX4 Pharmaceuticals to Participate in Guggenheim, Stifel and Jefferies Healthcare ConferencesX4 Pharmaceuticals will participate in three healthcare conferences: a Guggenheim fireside chat on Nov. 10, a Stifel fireside chat on Nov. 12, and a Jefferies London presentation on Nov. 16. The company will join each event at the specified times.Stock TitanX4 Pharmaceuticals to Join 3 Investor ConferencesX4 Pharmaceuticals announced management will participate in three investor conferences in November 2026: Guggenheim, Stifel, and Jefferies. The company, focused on rare hematology diseases, will present on its approved CXCR4 antagonist mavorixafor and ongoing Phase 3 trial.GlobeNewswireX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026X4 Pharmaceuticals announced management will participate in Guggenheim, Stifel, and Jefferies conferences in November 2026. The company's mavorixafor is approved for WHIM syndrome and has Fast Track designation for chronic neutropenia. A global Phase 3 trial (4WARD) is ongoing.Business & FinancialX4 Pharmaceuticals To Participate In Guggenheim, Stifel, And Jefferies Conferences In November 2026X4 Pharmaceuticals will present at Guggenheim, Stifel, and Jefferies conferences in November 2026. The company's mavorixafor is approved for WHIM syndrome and is in a global Phase 3 trial for chronic neutropenia, with Fast Track designation from the FDA.MarketBeatX4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic NeutropeniaX4 Pharmaceuticals expects to complete enrollment in its Phase III 4WARD trial of mavorixafor for chronic neutropenia by Q4 2026, with top-line data in Q1 2028. The company said positive results could support FDA approval in late 2028 or early 2029, and it has cash runway into 2029.TradingViewX4 Pharmaceuticals Outlines Mavorixafor Milestones and 2028 Trial DataX4 Pharmaceuticals outlined mavorixafor development milestones, including pivotal Phase 3 data expected in Q1 2028 and potential U.S. approval in late 2028 or early 2029. The 4WARD Phase 3 trial will reach full enrollment of 126 patients by Q4 2026, with topline data anticipated in Q1 2028. X4 plans to initiate the 4STEPS Phase 2b G-CSF dose-reduction trial in Q1 2027.Ticker ReportCritical Review: X4 Pharmaceuticals (NASDAQ:XFOR) & Entrada Therapeutics (NASDAQ:TRDA)X4 Pharmaceuticals outperforms Entrada Therapeutics on 8 of 13 factors, including higher revenue and lower valuation. X4's consensus target price implies a 311.33% upside versus Entrada's 270.56%. X4's lead candidate mavorixafor is in Phase III trials for rare diseases.Ticker ReportX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Has Consensus Target Price of $11.25 According to BrokeragesX4 Pharmaceuticals shares have a consensus 'Moderate Buy' rating with a $11.25 price target. Insiders sold 83,779 shares in the last 90 days, while institutional investors own 72.03% of the stock. The company reported Q2 EPS of -$0.13, beating estimates.YahooX4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersX4 Pharmaceuticals will host a virtual Investor Day on October 29, 2026, featuring management and key opinion leaders on mavorixafor for chronic neutropenia. The event will review the Phase 3 4WARD trial and outline a planned Phase 2 trial of mavorixafor with G-CSF. The company also presented the potential commercial opportunity for mavorixafor in chronic neutropenia.